Introduction
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an apoptosis-inducing member of the tumor necrosis factor (TNF) gene family, based on amino acid homology to TNF and FasL (Wiley et al., 1995; Pitti et al., 1996) . The apoptotic signal of TRAIL is transduced by binding to the death receptors DR4 and DR5. TRAIL also binds DcR1 and DcR2, which act as decoy receptors by inhibiting TRAIL signaling (Pan et al., 1997a,b; Sheridan et al., 1997; Walczak et al., 1997; Degli-Esposti et al., 1997a,b; Marsters et al., 1997) . Both DR4 and DR5 contain death domains in their cytoplasmic tail, and can initiate apoptotic signal pathways. In contrast to DR4 and DR5, DcR1 and DcR2 have no cytoplasmic tail and a truncated form, respectively (Pan et al., 1997a) . DcR1 and DcR2 have extracellular domains which are highly homologous to those of DR4 and DR5, but they fail to induce apoptosis upon binding TRAIL. Preclinical studies in mice and nonhuman primates have shown that administration of TRAIL induces apoptosis in a wide variety of tumors with no cytotoxicity to normal organs or tissues Walczak et al., 1999) . Dierential sensitivity between normal and tumor cells to TRAIL has been explained by the presence of a high concentration of the decoy receptors in normal cells (Gura, 1997; Ashkenazi and Dixit, 1999) . Recently, this hypothesis has been challenged based on poor correlations between DR4, DR5, and DcR1 expression and sensitivity to TRAIL-induced apoptosis in normal and cancerous breast cell lines (Keane et al., 1999) . It has also been reported that TRAIL induces apoptosis in normal human hepatocytes in culture, but not in hepatocytes isolated from the other species (Jo et al., 2000) . Obviously, more studies are needed for clari®cation of the mechanisms of TRAIL-induced apoptosis.
Recently, Scadi et al. (1998) reported two dierent CD95 (APO-1/Fas) signal transduction pathways leading to apoptosis: mitochondria-dependent and -independent. Overexpression of Bcl-2 inhibited the mitochondria-dependent pathway but not the mito-chondria-independent pathway. Recent studies also revealed that the Fas-associated death domain (FADD) is required for TRAIL-induced apoptosis (Kuang et al., 2000; Sprick et al., 2000; Kischkel et al., 2000) . These observations suggest that the TRAIL receptor and Fas-mediated apoptosis share the same death signal pathway. Thus, TRAIL-induced apoptosis is probably mediated through both mitochondriadependent and -independent pathways.
Nitric oxide (NO) is synthesized by members of the NO synthase family (Geller and Billiar, 1998) . NO reacts with superoxide to form peroxynitrite (Stamler et al., 1992) which is an extremely reactive and cytotoxic free radical compound. It can cause the induction of cytotoxicity and apoptotic death in lymphocytes (Albina et al., 1993; Blanco et al., 1995; Fehsel et al., 1995; Messmer et al., 1995) and tumor cells (Lin et al., 1995; Ho et al., 1996) , but not in hepatocytes . NO-triggered apoptosis is mediated through activation of caspases (Chlichlia et al., 1998) . Recent studies show that nitric oxide induces apoptosis via triggering mitochondrial permeability (Hortelano et al., 1997; Bal-Price et al., 1999; Brookes et al., 2000) . In this study, we hypothesized that nitric oxide enhances TRAIL-induced apoptosis by promoting mitochondria-dependent apoptotic process. To test the hypothesis, we chose sodium nitroprusside (SNP), a clinically approved compound primarily used for the treatment of acute hypertension and in vascular surgery. It is well known that SNP releases at least two physiologically active compounds, namely cyanide and nitric oxide species. Our studies demonstrate that SNP enhances TRAIL-induced apoptosis via a mitochondrial pathway by increasing cytochrome c release and caspase activation. Nitric oxide species, but not cyanide, are involved in this process.
Results

Effect of SNP on TRAIL-induced cytotoxicity
To investigate the eect of nitric oxide on TRAILinduced cytotoxicity, human colorectal carcinoma CX-1 cells were treated with sodium nitroprusside (SNP), a nitric oxide donor, along with TRAIL. Figure 1a ,d and e show that little or no toxicity was observed with SNP alone up to 1 mM. In contrast, TRAIL-induced cell death was concentration dependent (Figure 1b) . Interestingly, the survival curve became biphasic as the TRAIL dose was increased. These results indicate that the cytotoxic eect of TRAIL saturates at approximately 100 ng/ml (Figure 1b, d) . In other words, approximately 40% of the cell population was resistant to TRAIL. However, SNP enhanced TRAIL-induced cytotoxicity when cells were treated with both drugs (Figure 1c ± e) . For example, the survival fraction decreased to less than 2% with the treatment of TRAIL (200 ng/ml) and SNP (2 mM) for 12 h by colony formation assay (Figure 1c) . Similar results were observed by Trypan blue exclusion assay (Figure 1e ). These data suggest that SNP sensitizes the TRAIL-resistant subpopulation to killing by TRAIL.
Effect of SNP on TRAIL-induced apoptosis
It is well known that TRAIL-induced apoptosis and the TRAIL death pathway are mediated through a caspase cascade. To examine whether SNP enhances TRAIL-induced cytotoxicity through increasing in the activation of caspase, several caspases which are known to be involved in TRAIL-induced apoptosis were examined. Figure 2 demonstrates that SNP enhanced TRAIL-induced caspase 8 activation. Enzyme activity assays show that caspase 8 was rapidly activated within 15 min and maintained a steady state level during TRAIL treatment (Figure 2b ). Caspase 8 activation was promoted by 1 mM SNP. Western blot analysis shows that procaspase 8 (55/54 kDa), precursor form of caspase 8, was cleaved to the intermediates (43 and 41 kDa) and active form (18 kDa) in the presence of TRAIL, while 1 mM SNP alone did not activate caspase 8 (Figure 2a ). Quantitative measurement of proteins by Western blotting shows that TRAIL-induced formation of active caspase 8 was increased 4.1-fold in the presence of 1 mM SNP. Similar results were also observed in TRAIL-induced cytochrome c release. As shown in Figure 3a , TRAIL-induced cytochrome c release from mitochondria was increased in the presence of SNP. Several researchers have reported that cytochrome c in the cytoplasm binds to Apaf-1, which then permits recruitment of procaspase 9. Oligomerization results in autoactivation of caspase 9 (Zou et al., 1999; Saleh et al., 1999) . Our studies demonstrate that caspase 9 is activated by TRAIL treatment, this activation is promoted by SNP (Figure 3b ). Previous studies reveal that caspase 9 cleaves and activates procaspase 3 (Slee et al., 1999) . Thus, we further investigated whether TRAIL activates caspase 3. Enzyme activity assays and Western blot analysis show that caspase 3 was activated during TRAIL treatment (Figure 4a ,b). Our data clearly illustrate that cleavage of procaspase 3 (32 kDa) was promoted in the presence of SNP. We extended our studies to investigate caspase-mediated cleavage of poly(ADP-ribose) polymerase (PARP). PARP (116 kDa) was cleaved yielding a characteristic 85 kDa fragment in the presence of TRAIL ( Figure  4c ). This cleavage was enhanced by SNP treatment (see TRAIL+SNP vs TRAIL in Figure 4c ). Figure 4 also clearly demonstrates that 1 mM SNP alone did not activate caspase 3 and did not cleave PARP. Because SNP can release both nitric oxide and cyanide, the enhancing eect of SNP on TRAILinduced PARP cleavage was compared to treatment with the cyanide-releasing compound KCN in CX-1 cells. The combined treatment with SNP and TRAIL increased the TRAIL-induced cytotoxicity ( Figure 5a ) as well as PARP cleavage (Figure 5b ). However, unlike SNP, KCN did not enhance TRAIL-induced cytotoxicity ( Figure 5a ) and PARP cleavage ( Figure  5b ). These results suggest that enhancement of apoptotic death by SNP treatment is due to nitric oxide. Indeed, peroxynitrite and hydrogen peroxide also enhance TRAIL-induced apoptotic death (data not shown).
Effect of SNP on the level of TRAIL receptor family
It is well known that TRAIL can interact with two death receptors (DR4 and DR5), which trigger apoptotic signals (Pan et al., 1997a) . Such signals may be blocked by expression of the antagonistic decoy receptors (DcR1 and DcR2) (Pan et al., 1997b) . Previous studies also demonstrate that increased DR5 expression by chemotherapeutic agents is responsible for synergistic cytotoxicity with TRAIL (Nagane et al., 2000) . Thus, we examined whether treatment with TRAIL in combination with SNP may aect the level of TRAIL receptors. Cells were treated with 200 ng/ml TRAIL and 1 mM SNP for various times (3 or 5 h) and each receptor level was determined. Western blot analysis revealed that the combination treatment did not signi®cantly change the level of receptors (DcR2, DR4 and DR5) ( Figure  6 ).
Effect of SNP on the level of FLIP
Recent studies have demonstrated that TRAILinduced apoptosis is controlled by FLICE-inhibitory protein (FLIP) (Grith et al., 1998) . Reduction of the intracellular FLIP concentration sensitizes TRAILresistant human melanoma cells to TRAIL. Thus, we investigated whether treatment with TRAIL in combination with SNP alters the level of FLIP. Cells 
Effect of SNP is mediated through mitochondria
To further evaluate the eect of SNP on the TRAILinduced caspase cascade, Bcl-2 was overexpressed in CX-1 cells (Figure 8a ). Figure 8 shows that TRAILinduced cytotoxicity was not signi®cantly inhibited by Bcl-2 overexpression. However, the enhancing eect of SNP on TRAIL-induced cell death was signi®-cantly suppressed by Bcl-2 overexpression ( Figure  8b ). These results indicate that TRAIL induces apoptosis by two dierent signaling pathways; a mitochondria-dependent pathway and a mitochondria-independent pathway. Our data also suggest that SNP enhances TRAIL-induced apoptotic death through a mitochondria-dependent pathway. This hypothesis was tested as described in Figure 9 . The enhanced eects of SNP on TRAIL-induced cytochrome c release, caspase activation, and PARP cleavage were completely inhibited by overexpression of Bcl-2. However, Bcl-2 did not inhibit TRAIL-induced caspase activation and PARP cleavage. These results indicate that Bcl-2 failed to block the TRAIL-induced mitochondria-independent apoptosis pathway ( Figure 9 ). Bcl-2 only blocked the promoting eect of SNP on TRAIL by inhibiting mitochondria-dependent apoptosis.
Schematic diagram of apoptosis pathways induced by TRAIL and SNP
Our experimental data were summarized in Figure 10 . In this model, there are two possible pathways of TRAIL-induced apoptotic death. Caspase 8 may mediate the crosstalk between two pathways. Our data indicate that SNP promotes the TRAILinduced mitochondria-dependent apoptotic pathway by enhancing cytochrome c release. This eect is completely inhibited by overexpression of Bcl-2. 
Discussion
Several researchers have shown that TRAIL-induced cytotoxicity can be augmented by treatment with chemotherapeutic agents (Keane et al., 1999 , Nagane et al., 2000 and ionizing radiation (Chinnaiyan et al., 2000) . The synergistic eect may result from an increase in DR5 gene expression or decrease in FLIP expression in response to genotoxic stress (Sheikh et al., 1998; Nagane et al., 2000; Chinnaiyan et al., 2000) . However, our results from Figures 6 and 7 demonstrate that SNP-enhanced TRAIL cytotoxicity is not related to alterations of TRAIL receptor levels as well as FLIP level. Rather, it is probably due to enhanced apoptotic signaling via a mitochondria-dependent pathway. Overexpression of Bcl-2, which is known to inhibit the mitochondria-dependent pathway, clearly inhibits the promoting eect of SNP but not TRAIL-induced apoptotic death and caspase activation in human colorectal carcinoma CX-1 cells (Figures 8 and 9 ). Total cell lysates were subjected to immunoblotting analysis for TRAIL receptors using speci®c anti-functional receptors (DR4, DR5) and decoy receptor (DcR-2) antibodies. C, untreated control; S, 1 mM SNP; T, 200 ng/ml TRAIL; T+S, 200 ng/ml TRAIL and 1 mM SNP Similar results were observed in multiple myeloma cell lines (Gazitt et al., 1999) . TRAIL, TNF-a, and Fas ligand-induced apoptotic signals are not blocked by Bcl-2 in 8226 and ARP-1 myeloma cells (Gazitt et al., 1999) . Unlike in myeloma cells, Bcl-2 can block Fas ligand-mediated apoptotic cell death in human glioma cells (Weller et al., 1995) and murine lymphoma cells (Itoh et al., 1993) . These observations suggest that TRAIL-induced apoptosis is mediated through two dierent apoptotic pathways, mitochondria-dependent and -independent. Dependent upon cell type, one of the apoptotic pathways may be more prominent in mediating TRAIL's eects. Thus, dierences between the cell types must lie in the signaling pathways. Our studies indicate that TRAIL-induced apoptosis is primarily dependent upon a mitochondria-independent pathway in CX-1 cells (Figures 8 and 9 ). Caspase 8 can directly cleave and activate caspase 3 in this type cell .
As shown in Figure 1b , the survival curve became biphasic as the TRAIL concentration was increased. The biphasic survival curve indicates either the presence of two dierent populations (TRAIL resistance or sensitive) or the development of resistance during TRAIL treatment. When human prostate carcinoma DU-145 cells were pretreated with TRAIL, resistance to a second TRAIL exposure developed, reaching a maximum within 8 h, and decaying after 24 h to a second TRAIL exposure (unpublished data). These results suggest the development of TRAIL resistance rather than selection of a TRAIL resistant population during TRAIL treatment. Recent studies have shown that TNF-a stimulates the expression of SCC-S2, a novel anti-apoptotic protein (Kumar et al., 2000) . This molecule is highly homologous to the Fasassociated death domain-like interleukin-1b-converting enzyme-inhibitory protein (FLIP). Overexpression of cellular FLIP is also known to suppress Fas ligand and TNF-a-induced apoptosis Irmier et al., 1997) . Fas-associated phosphatase-1 The cells were incubated in the presence of 200 ng/ml TRAIL alone or with 1 mM SNP for 12 h and then the survival of the cells was measured. The results represent the mean and s.e. for three independent experiments Figure 9 Eects of Bcl-2 on the TRAIL-induced apoptosis signal transduction pathway. Control vector transfected (CX-1/ Neo) or Bcl-2 transfected (CX-1/bcl-2) cells were incubated in the presence of 1 mM SNP alone, 200 ng/ml TRAIL alone, or a combination of 1 mM SNP and 200 ng/ml TRAIL for 3 h, and then harvested by two dierent methods depending on target proteins. Total cell lysates were subjected to immunoblotting for caspase-3, caspase-8, and PARP. Cytosolic fractions were used for detecting cytosolic cytochrome c. Immunoblots of caspases show the protein levels of the inactive and active forms (see Figures 2 and 4) , whereas the blot of PARP indicates 116 kDa PARP (upper bands) and the 85 kDa apoptosis-related cleavage fragment (lower bands) (FAP-1) expression also correlates with resistance to Fas-mediated apoptosis (Zhou et al., 1998) . Thus, additional experiments are needed to clarify whether the combined treatment of TRAIL and SNP downregulates the expression of these anti-apoptotic molecules.
In this study, we observed that sublethal doses of SNP itself do not induce apoptosis or caspase activation. However, it enhances TRAIL-induced mitochondria-dependent death signals. At this time, we can only speculate how SNP promotes TRAILinduced apoptosis. Several studies have shown that NO stimulates apoptosis through activation of caspases (Tamatani et al., 1998) , cytochrome c release (Ushmorov et al., 1999) , changes in the expression of pro-and anti-apoptotic Bcl-2 family members (Tamatani et al., 1998; Brockhaus and Brune, 1999), and upregulation of the tumor suppressor p53 (Brockhaus and Brune, 1999) . Mitochondrial damage (lipid degradation, lipid peroxidation, and cytochrome c release) induced by NO plays a crucial role in the subsequent activation of caspase and apoptosis (Ushmorov et al., 1999; Ghafourifar et al., 1999a) . NO generates ceramide which induces cytochrome c release from mitochondria (Ghafourifar et al., 1999b) . However, recent studies have shown that NO may also protect cells. NO suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes and pulmonary artery endothelial cells (Ceneviva et al., 1998) . These studies suggest that the non-heme iron content in cells is a key factor in determining the consequences of NO on cell viability by regulating the chemical fate of NO . Thus, we Figure 10 Tentative model for the mechanism of TRAIL and SNP-induced apoptotic pathways postulate that the crosstalk between cell destructive and protective signaling pathways under the modulatory in¯uence of NO may determine the impact of NO on TRAIL-induced apoptotic cell death and survival. We believe that this model provides a framework for future studies.
Materials and methods
Reagents and antibodies
Polyclonal anti-FLIP and anti-caspase-3 antibodies were obtained from Calbiochem (San Diego, CA, USA) and Santa Crus Biotechnology (Santa Crus, CA, USA), respectively. Monoclonal antibodies were purchased from the following companies: anti-Bcl-2 from ICN (Costa Mesa, CA, USA), anti-cytochrome c from Pharmingen (San Diego, CA, USA), anti-caspase-8 from Upstate Biotechnology (Lake Placid, NY, USA), and anti-PARP from Biomol Research Laboratory (Plymouth Meeting, PA, USA). Sodium nitroprusside (SNP) and other chemicals were purchased from Sigma (St. Louis, MO, USA).
Cell culture and survival determination
The CX-1 cell line was obtained from the American Tissue Type Culture Collection (Manassas, VA, USA). Cells were cultured at 378C and 5% CO 2 in RPMI medium supplemented with 10% fetal calf serum, 50 U/ml penicillin, and 50 mg/ml streptomycin. For survival determination, cells were grown to subcon¯uence before treating with TRAIL and/or SNP. Cell viability was determined by colony formation assay or Trypan blue exclusion assay. For colony formation assay, cells were detached by treatment with ice cold 0.05% Trypsin and 0.53 mM EDTA in phosphate-buered saline solution (PBS). After detachment, the cells were resuspended in 3 ml of RPMI medium containing 10% fetal calf serum used as a Trypsin inhibitor. Cell counts were determined with a Coulter counter, and appropriate dilutions were made. The appropriate numbers of cells were plated into 60 mm dishes in duplicate to measure clonogenic cell survival. After 2 weeks of incubation, colonies (450 cells) were visualized with crystal violet staining. Data were normalized to untreated controls. For Trypan blue exclusion assay, trypsinized cells were pelleted and resuspended in 0.2 ml of RPMI medium, 0.5 ml of 0.4% Trypan blue solution and 0.3 ml of PBS. The samples were mixed thoroughly, incubated at room temperature for 15 min and examined.
Transfection
In order to generate Bcl-2 overexpressing CX-1 cells, cells were transfected with pcDNA3-Bcl-2 along with pcDNA3-neo using LipofectAMINE Plus (Gibco ± BRL Life Technologies, Grand Island, NY, USA). Transfected cells were selected for 3 weeks in growth medium containing 0.5 mg of G418 (Geneticin; Gibco ± BRL Life Technologies) per ml. The clone expressing the highest level of Bcl-2 was used for this study. The expression level was determined by immunoblot analysis.
Immunoblot analysis
Cell lysates were subjected to electrophoresis under reducing conditions, and the proteins in the gels were transferred onto polyvinylidine di¯uoride (PVDF) membranes. The membranes were incubated with 7% (w/v) skim milk in PBST (PBS containing 0.1% Tween 20, v/v) and then reacted with primary antibodies (diluted 1 : 1000 with PBST containing 1% BSA). After washing three times with PBST, the membranes were incubated with horseradish peroxidaseconjugated goat anti-IgG (1 : 5000). Proteins in the membranes were then visualized using the enhanced chemiluminescence (ECL) reagent (Amersham, Arlington Heights, IL, USA) as recommended by the manufacturer.
Caspase assay
Cells were harvested after incubation with TRAIL and/or SNP for the indicated periods at 378C, and then lysed in caspase lysis buer (0.03% Nonidet, 1 mM DTT, 50 mM Tris, pH 7.5). The insoluble fractions were removed by centrifugation for 5 min (800 g), and the cytosolic fractions were incubated with caspase reaction buer (50 mM NaCl, and 2.5 mM DTT, 20 mM HEPES, pH 7.5), containing 10 mM DEVD-amc for caspase-3-like activity, Ac-IETD-afc for caspase-8-like activity, or Ac-LEHD-afc for caspase-9-like activity, in a total volume of 200 ml for 100 min at 378C. Fluorescence, released by caspase activity, was measured using 360 nm excitation for amc or 400 nm for afc. The intensity at the optimum (450 nm for amc or 505 nm for afc) was measured using a Spectra Max Gemini Plate Reader (Molecular Devices, Sunnyvale, CA, USA). DEVDase activity was normalized to micrograms of protein, measured with a BCA protein assay kit (Pierce, Rockford, IL, USA).
Cytochrome c release
To measure the release of cytochrome c from mitochondria, subcon¯uent cells growing in 100 mm dishes were treated as indicated in Figures 3 and 9 . After the treatment, cells were scraped, washed in PBS, washed in buer H (20 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 2 mM dithiothreitol (DTT), 1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl¯uoride (PMSF), 1 mg/ml leupeptin, 1 mg/ml pepstatin, 10 mg/ml aprotinin) and resuspended in 200 ml buer H. After 1 h incubation on ice, cells were lysed by forcing them through a 27-gauge needle 15 ± 20 times. The lysate was centrifuged at 12 000 g for 15 min and the supernatant was collected. Cytochrome c levels in the resulting supernatant were analysed by immunoblotting.
Production of recombinant TRAIL
A human TRAIL cDNA fragment (amino acids 114 ± 281) obtained by RT ± PCR was cloned into a pET-23d (Novagen, Madison, WI, USA) plasmid, and expressed protein was puri®ed using the Ni-NTA His-Bind Resin Super¯ow according to the manufacturer's instructions (Novagen).
Abbreviations
The abbreviations used are: TRAIL, tumor necrosis factorrelated apoptosis-inducing ligand; SNP, sodium nitroprusside; TNF-a, tumor necrosis factor a; PARP, poly(ADPribose) polymerase; DTT, dithiothreitol; HEPES, 
